TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03208049

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Therapy (BT)
Description: Behavioral Therapy will regulate time spent in bed based on information collected from sleep diaries during evaluation and treatment. Behavioral therapy is designed to improve sleep quality by matching opportunity for sleep to the amount of average total sleep calculated from sleep diaries. Once the quality of sleep has improved, sleep quantity is gradually increased by slowly increasing sleep opportunity. Stimulus control will strengthen the bed/sleep association by eliminating non-sleep activities from the bedroom.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Therapy (CT)
Description: Cognitive Therapy is designed to identify maladaptive beliefs about sleep, challenge their validity, and replace them with more adaptive thinking patterns. This therapy aims to reduce sleep-related worry, anxiety, and fear. The treatment phase of the study lasts six weeks. During treatment, you will meet with a study therapist for a total of six sessions: once per week for six consecutive weeks. Each session lasts approximately 60 minutes.
Study: NCT00586391

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CD19CAR-28-zeta T cells
Description: Intravenous injection~Dose Level 1:~CD19CAR-28zeta - 2x10\^7 cells/m\^2~Dose Level 2:~CD19CAR-28zeta - 1 x10\^8 cells/m\^2~Dose Level 3:~CD19CAR-28zeta - 2x10\^8 cells/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: For patients with intermediate or low grade leukemia/lymphoma, patients may receive ipilimumab once during the week 2 visit after the T cell infusion.
Study: NCT03643107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irofulven
Description: Irofulven will be administered as an intravenous dose of 0.45 mg/kg, over a 30-minute infusion period by venous access at day 1 and 8 of a three week cycle.~Irofulven will be administered in combination with a daily dose of 10 mg orally administered prednisolone.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Prednisolone 10 mg
Description: Irofulven will be administered as an intravenous dose of 0.45 mg/kg, over a 30-minute infusion period by venous access at day 1 and 8 of a three week cycle.~Irofulven will be administered in combination with a daily dose of 10 mg orally administered prednisolone.
Study: NCT01058863

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Inhaler
Description: Placebo delivered in both the Spiromax® and HFA inhalers to maintain the blind and also to support the placebo treatment arm.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Inhaler
Description: Placebo delivered in both the Spiromax® and HFA inhalers to maintain the blind and also to support the placebo treatment arm.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Inhaler
Description: Placebo delivered in both the Spiromax® and HFA inhalers to maintain the blind and also to support the placebo treatment arm.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Inhaler
Description: Placebo delivered in both the Spiromax® and HFA inhalers to maintain the blind and also to support the placebo treatment arm.
Study: NCT02254850

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Flow Mediated Dilation
Description: Patients performed FMD by an high-resolution ultrasound linear probe in a supine decubitus and conditioned room.The probe was placed on humeral artery and connected to a mechanically arm. Then were performed several measurement s of the internal diameter of the vessel (edge to edge distance), on the R wave of the ECG, and software calculated the average value.The post-ischemic vasodilation was induced using a sphygmomanometer placed on the forearm, distal to the elbow crease, kept inflated to 250 mmHg for 5 minutes. The flow rate was recorded immediately after the desufflation; the diameter of the brachial artery was measured several times after desufflation (for 60-90 seconds). Nextly, the FMD was calculated as the percentage difference between the maximum diameter of the post-ischemic reached and the mean diameter of the vessel.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Flow Mediated Dilation
Description: Patients performed FMD by an high-resolution ultrasound linear probe in a supine decubitus and conditioned room.The probe was placed on humeral artery and connected to a mechanically arm. Then were performed several measurement s of the internal diameter of the vessel (edge to edge distance), on the R wave of the ECG, and software calculated the average value.The post-ischemic vasodilation was induced using a sphygmomanometer placed on the forearm, distal to the elbow crease, kept inflated to 250 mmHg for 5 minutes. The flow rate was recorded immediately after the desufflation; the diameter of the brachial artery was measured several times after desufflation (for 60-90 seconds). Nextly, the FMD was calculated as the percentage difference between the maximum diameter of the post-ischemic reached and the mean diameter of the vessel.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesoglycan
Description: The Patients firstly underwent to intramuscular administration of 1 vial only, containing: Mesoglycan 30mg/ml.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesoglycan
Description: The patients underwent to oral treatment with 1 capsule, administered bis in die for a period of 90 days, containing: Mesoglycan 50 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The Patients firstly underwent to intramuscular administration only of 1 vial containing inactive ingredients: sodium chloride, chlorocresol, water for injections.
Study: NCT03451799

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketogenic Diet
Description: A 4-month ketogenic diet will be supervised and monitored by the study investigators. Study dietitians will create personalized meal plans for each patient with the goal of achieving and maintaining metabolic ketosis.
Study: NCT02254850

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The patients underwent to oral treatment with 1 capsule, administered bis in die for a period of 90 days, containing inactive ingredients: lactose monohydrate, corn starch, croscarmellose sodium, magnesium stearate, gelatin, titanium dioxide, erythrosine.
Study: NCT03653416

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ipack
Description: IPACK block - local anesthesia injected safely under ultrasound guidance in the interspace between the popliteal artery and capsule of the knee.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: 20 cc of bupivacaine(o.25%) injection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peri Articular Infiltration
Description: Adductor Canal Catheter and Peri Articular Infiltration
Study: NCT03451799

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Standard-of-care radiation
Description: Patients will receive standard-of-care radiation. Radiation is not protocol directed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard-of-care Temozolomide
Description: Patients will receive standard-of-care temozolomide. Temozolomide is not protocol directed.
Study: NCT00746395

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lubiprostone
Description: 24 mcg oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration
Study: NCT03653416

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Peri Articular Infiltration
Description: Adductor Canal Catheter and Peri Articular Infiltration
Study: NCT00715507

Intervention type: DEVICE
Intervention: medication monitor
Description: the medication monitor will aid in expertise and decision-making.
Study: NCT00416923

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Study: NCT00658736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone
Description: Injection of bupivacaine and triamcinolone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivicaine alone
Description: Injection of bupivacaine
Study: NCT03859336

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transdermal Neuromodulation Stimulation
Description: The TEN device administers a tuned high frequency electrical stimulation delivered to the cervical plexus (C2-C4) on the back of the neck for 20 minutes. This stimulation will activate common trigeminovagal pathways modulating noradrenergic signaling to attenuate sympathetic activity. This stimulation can subsequently regulate the activity of several deep-brain nuclei within the ascending reticular activating system (RAS). Nuclei in the RAS regulate powerful neuromodulators like norepinephrine (NE), acetylcholine (ACh), and serotonin (5-HT). The investigators will examine whether this modulation from TENS will decrease anxiety and improve sleep quality in the study participants.
Study: NCT01902589

Intervention type: OTHER
Intervention: Helicobacter Pylori Culture
Description: Biopsy specimens for histology will be fixed in formalin, embedded in paraffin and sectioned and stained with hematoxylin and eosin.~The microbiological workup will include an imprint of the biopsy on a slide followed by a gram stain for the purpose of demonstrating H. pylori in situ. Further the biopsies will be streaked out on chocolate agar, Sheep blood agar and H. pylori selective agar supplemented with Polymixin to suppress possible contaminants.~4 days of incubation in a micro aerophilic atmosphere will follow . Susceptibility testing of H pylori will be performed with E test on Mueller Hinton agar supplemented with defibrinated sheep blood using a MacFalrland 3.0 density of a bacterial suspension. Reading the susceptibility will take place following 72 hours of incubation in a micro aerophilic atmosphere.
Study: NCT04616326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galcanezumab
Description: Administered SQ

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SQ
Study: NCT04432012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Sodium Phosphate 4 mg/ml intravenous
Description: Perioperative intravenous injection of 3 ml of solution (9mg of dexamethasone)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Sodium Phosphate 4 mg/ml intra-articular
Description: Perioperative intra-articular injection of 3 ml of solution (9mg of dexamethasone)
Study: NCT03742089

Intervention type: DEVICE
Intervention: Bone Anchored Hearing Surgery
Description: This is a observational study of pediatric patients undergoing bone anchored hearing surgery. The collected will be used to assess the implant stability development of the Ponto BHX implant during up to 24 months after implantation in a pediatric population undergoing BAHS. The study will also monitor the Ponto BHX implant safety and survival throughout the study period.
Study: NCT03562832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PARP inhibitor 2X-121
Description: 600 mg PARP inhibitor 2X-121 as single daily oral agent in mBC patients
Study: NCT03995628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: One dose of dexamethasone (0.5 mg/kg) on post-operative day 3 after tonsillectomy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One dose of placebo on post-operative day 3 after tonsillectomy
Study: NCT03983278

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: School Model
Description: Free delivery of glasses at the school within two weeks after screening

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Referral Model
Description: After the primary screening children referred to nearby Vision Center/ secondary center for refraction and delivery of free glasses.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Referral Model + Cost Recovery
Description: After the screening children referred to Vision Center for refraction and delivery of free glasses with the option to purchase upgrade glasses
Study: NCT02810197

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychopathological assessment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychopathological assessment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuropsychological assessment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuropsychological assessment

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional magnetic resonance imaging (fMRI)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional magnetic resonance imaging (fMRI)
Study: NCT02718326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injection [IAI]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injection [IAI]
Study: NCT01739595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enclomiphene citrate
Description: oral, capsules, taken one time daily, for 3 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsule taken one time daily for 3 months
Study: NCT02001012

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether-lumefantrine combination

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine
Study: NCT02255630

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cycling Exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cycling Exercise
Study: NCT00101569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Tablets, Oral, 15 -30 mg, once daily, 2 weeks (days 1 -14).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Oral Solution, Oral, 15-30 ml, once daily, 1 week (days 15 -21).
Study: NCT03729349

Intervention type: BIOLOGICAL
Intervention: Golimumab
Description: Participants will receive golimumab as a part of clinical practice.
Study: NCT00788255

Intervention type: DRUG
Intervention: Final exogenous oxytocin concentration=22.5 μU/mL
Description: Citrated whole blood 1mL + 23μU oxytocin. After mixing by inversion 8-10 times, 360μL kaolin-activated blood of each study solution was pipetted into a plastic cup in a prewarmed Thromboelastograph® (37°C). Each sample was recalcified in a plastic cup with 10μL of CaCl2 6.45%, and TEG® analysis was commenced within 1 minute of reconstituted sample preparation.
Study: NCT02718326

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham
Study: NCT00788255

Intervention type: DRUG
Intervention: Final exogenous oxytocin concentration=30.1μU/mL
Description: Citrated whole blood 1mL + 31μU oxytocin. After mixing by inversion 8-10 times, 360μL kaolin-activated blood of each study solution was pipetted into a plastic cup in a prewarmed Thromboelastograph® (37°C). Each sample was recalcified in a plastic cup with 10μL of CaCl2 6.45%, and TEG® analysis was commenced within 1 minute of reconstituted sample preparation.

Intervention type: DRUG
Intervention: Final exogenous oxytocin concentration=32.9μU/mL
Description: Citrated whole blood 1mL + 34μU oxytocin. After mixing by inversion 8-10 times, 360μL kaolin-activated blood of each study solution was pipetted into a plastic cup in a prewarmed Thromboelastograph® (37°C). Each sample was recalcified in a plastic cup with 10μL of CaCl2 6.45%, and TEG® analysis was commenced within 1 minute of reconstituted sample preparation.
Study: NCT02742506

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electroencephalography (EEG)
Description: EEG will be performed to assess brain activity in response to sounds of different nature, including music and the given name of the registered person

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electroencephalography (EEG)
Description: EEG will be performed to assess brain activity in response to sounds of different nature, including music and the given name of the registered person
Study: NCT03509922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anplag Tab. 100mg bid
Description: sarpogrelate hydrochloride 100mg bid for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anplag Tab. 100mg tid
Description: sarpogrelate hydrochloride 100mg tid for 24 weeks
Study: NCT00972179

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by subcutaneous or intravenous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tezepelumab
Description: Administered by subcutaneous or intravenous injection
Study: NCT01878565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug
Description: Given four times in week 0, 4, 12 and 24. At each time of treatment, the patients will be hospitalized and treated with 800 unit of HBIG intramuscularly at day 0, 1, 2, 3 and 4, then were treated with 75 μg of GM-CSF subcutaneously at day 2, 3, 4, 5 and 6, and finally were injected 20 μg of HBV vaccine subcutaneously at day 6.

Intervention type: DRUG
Group type: OTHER
Intervention: GM-CSF control
Description: Given four times in week 0, 4, 12 and 24. At each time of treatment, the patients will be hospitalized and treated with saline placebo intramuscularly or subcutaneously at day 2, 3, 4, 5, 6.
Study: NCT05671900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine 1000 mg, Docetaxel 37.5g
Description: 6 weekly instillations of gemcitabine (1 gram of gemcitabine in 50 ml of sterile water) followed immediately by docetaxel (37.5 mg of docetaxel in 50 mL of saline) and subsequent monthly maintenance installations for those with no evidence of disease.
Study: NCT02211157

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high fat breakfast
Study: NCT00308282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2127399
Description: 30 mg, 60 mg or 160 mg, IV (in the vein) in weeks 0, 3 and 6. Treatment duration: 6 weeks.
Study: NCT04429750

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate umbilical cord clamping
Description: In the immediate cord clamping group, the umbilical cord will be clamped within the first 20 seconds after birth and the infant will be transferred to the resuscitation room. The newborn infant will be intubated and mechanically ventilated as quickly as possible on the resuscitation table as recommended in the French Programme National de Soins.~After cardiorespiratory stabilization (i.e. heart rate\>120/min, increasing preductal O2 saturation or achieving acceptable preductal SpO2 targets between 80 and 95%), the infant will be transferred to the neonatal intensive care unit (NICU). Oxytocin is infused to the mother as recommended in the local protocol (usually just after birth or cord clamping).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intact cord resuscitation
Description: The umbilical cord will be kept intact during the initial phase of the resuscitation. The infant will be placed on a specifically designed compact trolley with a warmed platform, suitable for commencing resuscitation between the mother's legs in case of vaginal birth or near the operating table beside the mother in case of cesarean section. This trolley will be fully equipped for resuscitation, including a suction device, gas flowmeter/blender, ventilatory support, and monitoring system. Its height can be adjusted in order to position the infant close to the maternal perineum. The infant will be intubated and mechanically ventilated on this trolley. The cord will be clamped once cardiorespiratory stabilization will be obtained (i.e. heart rate\>120/min, increasing preductal O2 saturation or achieving acceptable preductal SpO2 targets between 80 and 95%) or in case of spontaneous placental expulsion. The infant will be then transferred to the neonatal intensive care unit (NICU).
Study: NCT01538615

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HOME Plus intervention
Description: The HOME Plus program families will participate in monthly, two-hour group sessions for ten months at local community centers. Each session offers new ideas focusing on family meals, healthy eating, and reducing sedentary behavior. At each session, families prepare and eat a meal together and participate in small group discussions and activities for both parent and child groups to promote healthy behaviors in the home. Topics include planning healthy meals and snacks with your family, having meals with your family more often, and improving the healthfulness of the food available at home. Families also receive periodic supportive phone calls throughout the year using motivational interviewing techniques to promote healthy behaviors to prevent and reduce childhood obesity.
Study: NCT02212938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 14332 CL
Study: NCT01343004

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 0 mcg subcutaneous daily
Study: NCT02212938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 14332 CL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high fat breakfast
Study: NCT04193293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duvelisib
Description: Phosphoinositide 3-kinase (PI3K) Inhibitor

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Immunotherapy (programmed cell death protein 1 \[PD-1\] inhibitor)
Study: NCT01343004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BA058 80 mcg
Description: BA058 80 mcg subcutaneous daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: teriparatide
Description: teriparatide 20 mcg subcutaneous daily
Study: NCT03024086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWJ1252
Description: DWJ1252 and Placebo of Gasmotin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gasmotin
Description: Gasmotin and Placebo of DWJ1252
Study: NCT00910221

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet
Study: NCT04112823

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 4mg
Description: Dexamethasone 4mg + metoclopramide 10mg, intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 16mg
Description: Dexamethasone 16mg + metoclopramide 10mg, intravenously
Study: NCT00772603

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Non-active tablet identical to study drug tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2400mg SPN-804
Description: tablets containing 600mg OXC XR, identical to non-active tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1200mg SPN-804
Description: two active tablets and two non-active tablets, all identical